Treace reports 5-year Lapiplasty study data at AOFAS meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equities rebound to close higher as surging Treasury yields recede
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
September 17, 2026 5:16 PM EDTPONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (Treace or the Company) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced the presentation of the results from three clinical studies at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Seattle, Washington. The presentations include data on the milestone 5-year ALIGN3D® Lapiplasty®, the MTA3D® Adductoplasty® and the SPRINT SpeedPlate® clinical studies.
"We are proud to present a robust body of clinical evidence at... More
